125 related articles for article (PubMed ID: 1525595)
21. Endocrine and antitumor effects of combined treatment with an antiprogestin and antiestrogen or luteinizing hormone-releasing hormone agonist in female rats bearing mammary tumors.
Bakker GH; Setyono-Han B; Portengen H; De Jong FH; Foekens JA; Klijn JG
Endocrinology; 1989 Sep; 125(3):1593-8. PubMed ID: 2527151
[TBL] [Abstract][Full Text] [Related]
22. Luteinizing hormone-releasing hormone-binding sites in the rat thymus: characteristics and biological function.
Marchetti B; Guarcello V; Morale MC; Bartoloni G; Farinella Z; Cordaro S; Scapagnini U
Endocrinology; 1989 Aug; 125(2):1025-36. PubMed ID: 2546732
[TBL] [Abstract][Full Text] [Related]
23. Direct effects of luteinizing hormone-releasing hormone agonists and antagonists on MCF-7 mammary cancer cells.
Segal-Abramson T; Kitroser H; Levy J; Schally AV; Sharoni Y
Proc Natl Acad Sci U S A; 1992 Mar; 89(6):2336-9. PubMed ID: 1312718
[TBL] [Abstract][Full Text] [Related]
24. Direct inhibitory effect of a luteinizing hormone-releasing hormone agonist on MCF-7 human breast cancer cells.
Blankenstein MA; Henkelman MS; Klijn JG
Eur J Cancer Clin Oncol; 1985 Dec; 21(12):1493-9. PubMed ID: 3938397
[TBL] [Abstract][Full Text] [Related]
25. Fourteen-day versus twenty-one-day regimens of intermittent intranasal luteinizing hormone-releasing hormone agonist combined with an oral progestogen as antiovulatory contraceptive approach.
Lemay A; Faure N
J Clin Endocrinol Metab; 1986 Dec; 63(6):1379-85. PubMed ID: 2946711
[TBL] [Abstract][Full Text] [Related]
26. Evidence that ibuprofen antagonizes selective actions of estrogen and tamoxifen on rat bone.
Sibonga JD; Bell NH; Turner RT
J Bone Miner Res; 1998 May; 13(5):863-70. PubMed ID: 9610751
[TBL] [Abstract][Full Text] [Related]
27. Combined effects of buserelin, estradiol and tamoxifen on the growth of MCF-7 human breast cancer cells in vitro.
Foekens JA; Henkelman MS; Fukkink JF; Blankenstein MA; Klijn JG
Biochem Biophys Res Commun; 1986 Oct; 140(2):550-6. PubMed ID: 3096324
[TBL] [Abstract][Full Text] [Related]
28. Comparative effects of droloxifene, tamoxifen, and estrogen on bone, serum cholesterol, and uterine histology in the ovariectomized rat model.
Ke HZ; Chen HK; Simmons HA; Qi H; Crawford DT; Pirie CM; Chidsey-Frink KL; Ma YF; Jee WS; Thompson DD
Bone; 1997 Jan; 20(1):31-9. PubMed ID: 8988345
[TBL] [Abstract][Full Text] [Related]
29. Blockade of LH and FSH secretion by LH-releasing hormone, by the LH-releasing hormone analogue, buserelin, and by combined treatment with LH-releasing hormone and oestradiol benzoate.
Schuiling GA; Pols-Valkhof N; van der Schaaf-Verdonk GC; Koiter TR
J Endocrinol; 1984 Dec; 103(3):301-9. PubMed ID: 6438265
[TBL] [Abstract][Full Text] [Related]
30. Effects of an LHRH agonist on endocrine function, LHRH receptor and LH/hCG receptor in the pituitary-gonadal axis of male rats.
Komatsu M; Iwahana H; Mitsuhashi S
Endocrinol Jpn; 1986 Apr; 33(2):185-95. PubMed ID: 3019649
[TBL] [Abstract][Full Text] [Related]
31. Effects of gonadotropin-releasing hormone and its agonists on prolactin secretion from normal and tumorous pituitary cells.
Lamberts SW; Uitterlinden P; Reubi JC; de Jong FH
Neuroendocrinology; 1989 Feb; 49(2):157-63. PubMed ID: 2524674
[TBL] [Abstract][Full Text] [Related]
32. Raloxifene analog (LY117018 HCL) ameliorates cyclosporin A-induced osteopenia in oophorectomized rats.
Bowman AR; Sass DA; Marshall I; Ma YF; Liang H; Jee WS; Epstein S
J Bone Miner Res; 1996 Aug; 11(8):1191-8. PubMed ID: 8854256
[TBL] [Abstract][Full Text] [Related]
33. Dose-dependent effects of tamoxifen on long bones in growing rats: influence of ovarian status.
Moon LY; Wakley GK; Turner RT
Endocrinology; 1991 Sep; 129(3):1568-74. PubMed ID: 1874188
[TBL] [Abstract][Full Text] [Related]
34. Establishing an Animal Model of Secondary Osteoporosis by Using a Gonadotropin-releasing Hormone Agonist.
Mohamad NV; Che Zulkepli MAA; May Theseira K; Zulkifli N; Shahrom NQ; Ridzuan NAM; Jamil NA; Soelaiman IN; Chin KY
Int J Med Sci; 2018; 15(4):300-308. PubMed ID: 29511366
[No Abstract] [Full Text] [Related]
35. Treatment with buserelin, an agonist of gonadotropin-releasing hormone, suppresses ovarian hyperstimulation syndrome induced in rabbits.
Oshima K; Suzuki K; Makita S; Yoshida Y
Pharmacology; 2004 Nov; 72(3):184-9. PubMed ID: 15452367
[TBL] [Abstract][Full Text] [Related]
36. Effects of chronic prednisolone treatment on bone resorption and bone composition in intact and ovariectomized rats and in ovariectomized rats receiving beta-estradiol.
Goulding A; Gold E
Endocrinology; 1988 Feb; 122(2):482-7. PubMed ID: 3338411
[TBL] [Abstract][Full Text] [Related]
37. Anti-tumor and endocrine effects of chronic LHRH agonist treatment (Buserelin) with or without tamoxifen in premenopausal metastatic breast cancer.
Klijn JG; de Jong FH; Blankenstein MA; Docter R; Alexieva-Figusch J; Blonk-van der Wijst J; Lamberts SW
Breast Cancer Res Treat; 1984; 4(3):209-20. PubMed ID: 6435703
[TBL] [Abstract][Full Text] [Related]
38. Effect of LHRH agonist (buserelin) on pulsatile secretion of LHRH and LH.
Okuda K; Ushiroyama T; Yoshikawa M; Sugimoto O
Nihon Sanka Fujinka Gakkai Zasshi; 1988 Dec; 40(12):1889-93. PubMed ID: 3145318
[TBL] [Abstract][Full Text] [Related]
39. Effect of luteinizing hormone-releasing hormone analogs on the rat ovarian follicle development.
Yano T; Yano N; Matsumi H; Morita Y; Tsutsumi O; Schally AV; Taketani Y
Horm Res; 1997; 48 Suppl 3():35-41. PubMed ID: 9267814
[TBL] [Abstract][Full Text] [Related]
40. Effects of long-term treatment with estradiol or clomiphene citrate on bone maintenance, and pituitary and uterine weights in ovariectomized rats.
Chakraborty PK; Brown JL; Ruff CB; Nelson MF; Mitchell AS
J Steroid Biochem Mol Biol; 1991; 40(4-6):725-9. PubMed ID: 1958570
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
